COPD treatment relies on several categories of inhalers, each serving a different purpose. Some provide quick relief when breathing gets tight, others keep airways open around the clock, and combination inhalers bundle multiple medications into a single device. The right inhaler (or combination of inhalers) depends on the severity of your symptoms, how often you experience flare-ups, and specific markers in your blood that help predict which medications will work best for you.
Short-Acting Rescue Inhalers
Short-acting inhalers are the ones you reach for when symptoms flare up suddenly. They work within minutes and typically last four to six hours. There are two types: short-acting beta-agonists (SABAs) like albuterol, which relax the muscles wrapped around your airways, and short-acting muscarinic antagonists (SAMAs) like ipratropium, which reduce airway tightening through a different pathway. Some people carry a combination of both.
These inhalers are not designed for daily prevention. If you’re using a rescue inhaler more than a few times a week, that’s a signal your COPD may need a stronger maintenance plan.
Long-Acting Maintenance Inhalers
Maintenance inhalers are the backbone of daily COPD management. You take them on a schedule, usually once or twice a day, whether you feel short of breath or not. They come in two main classes that work through different mechanisms.
Long-acting beta-agonists (LABAs) relax the muscle bands that tighten around your airways, keeping them open for 12 to 24 hours per dose. Long-acting muscarinic antagonists (LAMAs) work on a different set of nerve signals. They reduce airway constriction and also help with cough and mucus production, which makes them particularly useful for COPD specifically. Many people start on one or the other, and which class you begin with often comes down to your most bothersome symptoms.
Dual Combination Inhalers
When a single maintenance inhaler isn’t enough, the next step is usually combining a LABA and a LAMA in one device. Rather than juggling two separate inhalers, dual combination products put both medications together. Several options are available:
- Stiolto Respimat (tiotropium/olodaterol), delivered as a soft mist
- Anoro Ellipta (umeclidinium/vilanterol), a dry powder inhaler
- Bevespi Aerosphere (glycopyrrolate/formoterol), a pressurized metered-dose inhaler
- Duaklir Pressair (aclidinium/formoterol), a dry powder inhaler
These dual inhalers open your airways through two complementary pathways at once. For many people with moderate COPD, this combination provides noticeably better breathing than either medication alone.
When Inhaled Steroids Are Added
Inhaled corticosteroids (ICS) reduce inflammation in the airways. Unlike bronchodilators, which physically open the tubes you breathe through, steroids calm the immune response that causes swelling and irritation. They’re not recommended for everyone with COPD, though. The decision to add a steroid hinges largely on a blood marker called the eosinophil count, which measures a specific type of white blood cell tied to airway inflammation.
Research from the European Respiratory Society suggests that people with eosinophil counts below 150 cells per microliter see little benefit from inhaled steroids and may face unnecessary side effects. The clearest benefit shows up at higher counts, particularly above 450 cells per microliter. Your doctor can check this with a routine blood test.
The reason for caution: long-term inhaled steroid use raises the risk of pneumonia. In the large TORCH study, people using an inhaled steroid experienced roughly 84 to 88 pneumonia cases per 1,000 treatment-years, compared to about 52 per 1,000 in groups not using steroids. The risk was higher in people over 55, those with more severe airflow limitation, lower body weight, and a history of frequent flare-ups. No increase in pneumonia deaths was observed in the combination treatment group, but the elevated infection rate is real and worth weighing.
Triple Therapy Inhalers
For people with more advanced COPD or frequent exacerbations, triple therapy combines all three medication classes in a single inhaler: a LAMA, a LABA, and an inhaled corticosteroid. Two single-inhaler triple therapy products are currently available:
- Trelegy Ellipta (fluticasone/vilanterol/umeclidinium), taken once daily
- Breztri Aerosphere (budesonide/glycopyrrolate/formoterol), taken twice daily
The convenience of one device instead of two or three makes a meaningful difference in real life. Simpler regimens tend to lead to more consistent use, which directly affects how well symptoms stay controlled.
Newer Treatment: Ohtuvayre
Approved by the FDA in 2024, Ohtuvayre (ensifentrine) is a maintenance treatment that works differently from any existing inhaler class. It both relaxes airway muscles and reduces inflammation, but it’s not a steroid. It blocks two enzymes that break down chemical signals your body uses to keep airways relaxed and calm. The result is wider airways and less inflammatory activity without the steroid-related pneumonia risk.
Ohtuvayre is delivered as a liquid through a standard jet nebulizer with a mouthpiece, not a handheld inhaler. The dose is one ampule twice daily. It’s designed for people who need maintenance therapy and may be added alongside other medications.
Inhaler Device Types and How They Differ
The medication inside matters, but so does the device that delivers it. The same drug can work well or poorly depending on whether you can use the device correctly. There are three main types.
Pressurized metered-dose inhalers (pMDIs) use a pressurized canister to push medication out in a spray. They require slow, steady breathing and good coordination between pressing the canister and inhaling. This coordination is harder than it sounds. A spacer, a tube that attaches to the inhaler, can help by holding the medication in a chamber so you don’t have to time everything perfectly, though studies show that more than 60% of patients still make technique errors even with a spacer.
Dry powder inhalers (DPIs) are breath-activated, meaning the device releases medication when you inhale. They require a quick, deep breath to pull the powder into your lungs. Most people find DPIs easier to use than pressurized inhalers, but older adults or those with severe COPD may not be able to inhale forcefully enough to get the full dose.
Soft mist inhalers (SMIs) produce a fine, slow-moving mist that deposits more medication in the airways compared to the other two types. They don’t depend on how hard you can breathe in, making them a good option for people with weak inspiratory flow. The trade-off: some SMI devices require hand strength to load, which can be difficult for people with arthritis or limited dexterity.
Getting the Most From Your Inhaler
Even the best medication won’t help if it doesn’t reach your lungs. Research published in the Journal of the COPD Foundation found that the most common mistake with pressurized inhalers is failing to breathe out fully before taking a puff, with about 66% of patients skipping this step. Around 42% don’t hold their breath long enough afterward, and 39% inhale too quickly instead of slowly and deeply. Over a third forget to shake the inhaler before use.
These aren’t minor issues. Each error reduces how much medication actually reaches your lower airways, where it’s needed. If your COPD doesn’t seem well-controlled despite being on the right medications, technique is one of the first things to revisit. Ask your pharmacist or respiratory therapist to watch you use your inhaler and correct any habits you may have picked up. Even one visit focused on technique can make a noticeable difference in how well your treatment works.